# Table of Contents

**Highlights of This Issue** 2503

**SPECIAL FEATURES**

**CCR Translations**

2505 Minimal Residual Disease in Breast Cancer: In Blood Veritas
Giulia Siravegna and Alberto Bardelli
See related article, p. 2643

**Molecular Pathways**

2508 Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson

2516 Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

**CCR Focus**

2524 The Language of Pharmacodynamics
Susan E. Bates

2525 Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
William Douglas Figg and David R. Newell

2530 Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
Daniel L. Hertz and Howard L. McLeod

2541 Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

2553 Circulating Tumor Cells: A Multifunctional Biomarker
Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

**HUMAN CANCER BIOLOGY**

2595 FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaociang Zheng, Yong Gao, Suyun Huang, and Keping Xie

2607 Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Uday S. Kammula

2617 miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Xuan Yu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoiyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

2631 Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2–Negative Feedback Loop Mechanism
Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2761</td>
<td>A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response</td>
<td>Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas</td>
</tr>
<tr>
<td>2773</td>
<td>In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas</td>
<td>Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm</td>
</tr>
<tr>
<td>2793</td>
<td>A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases</td>
<td>Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga</td>
</tr>
<tr>
<td>2805</td>
<td>Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff</td>
<td>Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhukowicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

**ABOUT THE COVER**

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.
Clinical Cancer Research

20 (10)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/20/10.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.